{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:40Z","timestamp":1791613660159,"version":"4.3.4"},"reference-count":317,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+\/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies, including multiple myeloma (MM). Nonetheless, NK cells are subjected to a variety of cancer defense mechanisms, leading to impaired maturation, chemotaxis, target recognition, and killing. This review aims to summarize the available and most current knowledge about cancer-related impairment of NK cell function occurring in MM.<\/jats:p>","DOI":"10.3389\/fimmu.2021.816499","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T04:49:54Z","timestamp":1641876594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Natural Killer Cells in the Malignant Niche of Multiple Myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Ondrej","family":"Venglar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Rodriguez","family":"Bago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Motais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25791","article-title":"Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification And Management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.056","article-title":"Treatment of Multiple Myeloma: A Comprehensive Review","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymph Myeloma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.078519","article-title":"Extramedullary Involvement in Multiple Myeloma","volume":"97","author":"Blade","year":"2012","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01343-w","article-title":"Limited Efficacy of Daratumumab in Multiple Myeloma With Extramedullary Disease","author":"Jelinek","year":"2021","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary Disease in Multiple Myeloma - Controversies and Future Directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","article-title":"Cytogenetics in Multiple Myeloma Patients Progressing Into Extramedullary Disease","volume":"97","author":"Besse","year":"2016","journal-title":"Eur J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK Cells for Cancer Immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02277-x","article-title":"Natural Killer Cell Therapy for Hematologic Malignancies: Successes, Challenges, and the Future","volume":"12","author":"Lamb","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00275","article-title":"Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy","volume":"11","author":"Ben-Shmuel","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02816","article-title":"The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3\/CD19-Depleted Grafts Improves Their Ex Vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation","volume":"10","author":"Heinze","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1617128","article-title":"Potential of NK Cells in Multiple Myeloma Therapy","volume":"12","author":"Khan","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01124","article-title":"The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1469-8","article-title":"Advantages and Clinical Applications of Natural Killer Cells in Cancer Immunotherapy","volume":"63","author":"Ames","year":"2014","journal-title":"Cancer Immunol Immunother CII"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-Generation Cell Therapies: The Emerging Role of CAR-NK Cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.12.006","article-title":"CD56-Enriched Donor Cell Infusion After Post-Transplantation Cyclophosphamide for Haploidentical Transplantation of Advanced Myeloid Malignancies Is Associated With Prompt Reconstitution of Mature Natural Killer Cells and Regulatory T Cells With Reduced Incidence of Acute Graft Versus Host Disease: A Pilot Study","volume":"19","author":"Jaiswal","year":"2017","journal-title":"Cytother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-110312","article-title":"Autologous Antitumor Activity by NK Cells Expanded From Myeloma Patients Using GMP-Compliant Components","volume":"111","author":"Alici","year":"2008","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575609","article-title":"Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6437057","article-title":"Research Progress on NK Cell Receptors and Their Signaling Pathways","volume":"2020","author":"Chen","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02743","article-title":"Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma","volume":"9","author":"Tognarelli","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0724-5","article-title":"Interleukin-15 Enhances Natural Killer Cell Cytotoxicity in Patients With Acute Myeloid Leukemia by Upregulating the Activating NK Cell Receptors","volume":"59","author":"Szczepanski","year":"2010","journal-title":"Cancer Immunol Immunother CII"},{"key":"B22","unstructured":"Restoring NK Cell Activities in Multiple Myeloma With IL-15 Receptor Agonist NKTR-255 Alonso Fern\u00e1ndezR ASH2020"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04303-z","article-title":"Haploidentical Transplantation in Patients With Multiple Myeloma Making Use of Natural Killer Cell Alloreactive Donors","volume":"100","author":"Van Elssen","year":"2021","journal-title":"Ann Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical Efficacy and Management of Monoclonal Antibodies Targeting CD38 and SLAMF7 in Multiple Myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib9030034","article-title":"Monoclonal Antibodies in Cancer Therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.08.004","article-title":"Monoclonal Antibodies - A New Era in the Treatment of Multiple Myeloma","volume":"30","author":"Jelinek","year":"2016","journal-title":"Blood Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.030","article-title":"Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future","volume":"17","author":"Sherbenou","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a Novel Anti-CD38 Monoclonal Antibody, in Patients With Relapsed or Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1-2a Trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425146","article-title":"Comparative Analysis of NK Cell Subset Distribution in Normal and Lymphoproliferative Disease of Granular Lymphocyte Conditions","volume":"34","author":"Pascal","year":"2004","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","article-title":"Tissue Determinants of Human NK Cell Development, Function, and Residence","volume":"180","author":"Dogra","year":"2020","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00347","article-title":"Natural Killer Cell Distribution and Trafficking in Human Tissues","volume":"3","author":"Carrega","year":"2012","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.005","article-title":"Location and Cellular Stages of NK Cell Development","volume":"34","author":"Yu","year":"2013","journal-title":"Trends Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00360","article-title":"Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells","volume":"8","author":"Scoville","year":"2017","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural Killer Cells: Development, Maturation, and Clinical Utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"B36","article-title":"Generation of Natural Killer Cells From Bone Marrow Precursors","volume":"57","author":"Kalland","year":"1986","journal-title":"vitro Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.88","article-title":"Multi-Color Immune-Phenotyping of CD34 Subsets Reveals Unexpected Differences Between Various Stem Cell Sources","volume":"51","author":"Dmytrus","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.04.025","article-title":"Revision of the Human Hematopoietic Tree: Granulocyte Subtypes Derive From Distinct Hematopoietic Lineages","volume":"3","author":"G\u00f6rgens","year":"2013","journal-title":"Cell Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-318956","article-title":"Identification of the Earliest NK-Cell Precursor in the Mouse BM","volume":"117","author":"Carotta","year":"2011","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.immuni.2015.07.011","article-title":"Identification of a Human Natural Killer Cell Lineage-Restricted Progenitor in Fetal and Adult Tissues","volume":"43","author":"Renoux","year":"2015","journal-title":"Immun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12026-007-8006-9","article-title":"Extrinsic and Intrinsic Regulation of Early Natural Killer Cell Development","volume":"40","author":"Boos","year":"2008","journal-title":"Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348912","article-title":"Identification of the Earliest Natural Killer Cell\u2013Committed Progenitor in Murine Bone Marrow","volume":"118","author":"Fathman","year":"2011","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1038\/s41598-017-06238-4","article-title":"CD56 Is a Pathogen Recognition Receptor on Human Natural Killer Cells","volume":"7","author":"Ziegler","year":"2017","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-453969","article-title":"Mutations in GATA2 Cause Human NK Cell Deficiency With Specific Loss of the CD56bright Subset","volume":"121","author":"Mace","year":"2013","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1RU0514-241R","article-title":"Tissue-Specific NK Cell Populations and Their Origin","volume":"96","author":"Lysakova-Devine","year":"2014","journal-title":"J Leukoc Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21349","article-title":"Natural Killer Cell (NK) Subsets and NK-Like T-Cell Populations in Acute Myeloid Leukemias and Myelodysplastic Syndromes","volume":"90","author":"Aggarwal","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright Natural Killer (NK) Cells: An Important NK Cell Subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"NK Cell Biology: An Update and Future Directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040461","article-title":"Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities Into Potent Anti-Tumor Effects","volume":"11","author":"Bassani","year":"2019","journal-title":"Cancers"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)02060-9","article-title":"The Biology of Human Natural Killer-Cell Subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-282301","article-title":"CD57 Defines a Functionally Distinct Population of Mature NK Cells in the Human CD56dimCD16+ NK-Cell Subset","volume":"116","author":"Lopez-Verg\u00e8s","year":"2010","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409872102","article-title":"Characterization of CD56\u2013\/CD16+ Natural Killer (NK) Cells: A Highly Dysfunctional NK Subset Expanded in HIV-Infected Viremic Individuals","volume":"102","author":"Mavilio","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1742-4690-10-158","article-title":"CD56negCD16+NK Cells are Activated Mature NK Cells With Impaired Effector Function During HIV-1 Infection","volume":"10","author":"Milush","year":"2013","journal-title":"Retrovirology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1517","article-title":"CD27 Dissects Mature NK Cells Into Two Subsets With Distinct Responsiveness and Migratory Capacity","volume":"176","author":"Hayakawa","year":"2006","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03446.x","article-title":"CD11b and CD27 Reflect Distinct Population and Functional Specialization in Human Natural Killer Cells","volume":"133","author":"Fu","year":"2011","journal-title":"Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"208ra145","DOI":"10.1126\/scitranslmed.3006702","article-title":"Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry","volume":"5","author":"Horowitz","year":"2013","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.12.002","article-title":"Natural Killer Cells and Anti-Tumor Immunity","volume":"110","author":"Nicholson","year":"2019","journal-title":"Mol Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1615\/CritRevOncog.2014010805","article-title":"Positive and Negative Regulation by NK Cells in Cancer","volume":"19","author":"Sungur","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01143","article-title":"Natural Killer Cell Memory: Progress and Implications","volume":"8","author":"Peng","year":"2017","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.114","article-title":"Understanding of Molecular Mechanisms in Natural Killer Cell Therapy","volume":"47","author":"Yoon","year":"2015","journal-title":"Exp Mol Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5772\/intechopen.69729","article-title":"The Role of Activating and Inhibitory NK Cell Receptors in Antitumor Immune Response","volume":"69","author":"Konjevi\u0107","year":"2017","journal-title":"IntechOpen"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting Human Natural Killer Cell Subset Function Revealed Cytolytic CD56dimCD16+ NK Cells as Rapid Producers of Abundant IFN-\u03b3 on Activation","volume":"108","author":"Maria","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of Human NK-Cell Cytokine and Chemokine Production by Target Cell Recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.192","article-title":"Perforin and Interferon-Gamma Activities Independently Control Tumor Initiation, Growth, and Metastasis","volume":"97","author":"Street","year":"2001","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK Cell Cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","article-title":"Natural Killer Cell Cytotoxicity: How do They Pull the Trigger","volume":"128","author":"Topham","year":"2009","journal-title":"Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-111005","article-title":"Life and Death by Death Receptors","volume":"23","author":"Guicciardi","year":"2009","journal-title":"FASEB J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2005.05.002","article-title":"An Introduction to Death Receptors in Apoptosis","volume":"3","author":"Kumar","year":"2005","journal-title":"Int J Surg"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity in Solid Tumors: Biological Evidence and Clinical Perspectives","author":"Lo Nigro","year":"2019","journal-title":"Ann Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103726","article-title":"Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer","volume":"21","author":"Sordo-Bahamonde","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90097-s","article-title":"In Search of the \u201cMissing Self\u201d: MHC Molecules and NK Cell Recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK Cell Education by Inhibitory Receptors for MHC Class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.26","article-title":"NK Cell Education via Nonclassical MHC and Non-MHC Ligands","volume":"14","author":"He","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1917947117","article-title":"Broad and Thematic Remodeling of the Surfaceome and Glycoproteome on Isogenic Cells Transformed With Driving Proliferative Oncogenes","volume":"117","author":"Leung","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s0198-8859(99)00156-1","article-title":"The HLA Crossroad in Tumor Immunology","volume":"61","author":"Algarra","year":"2000","journal-title":"Hum Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.1998.00717.x","article-title":"Tumour Surveillance: Missing Peptides and MHC Molecules","volume":"76","author":"Khanna","year":"1998","journal-title":"Immunol Cell Biol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune Checkpoint Molecules in Natural Killer Cells as Potential Targets for Cancer Immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK Cells: Surface Receptors, Inhibitory Checkpoints, and Translational Applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6243819","article-title":"The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression","volume":"2020","author":"Zheng","year":"2020","journal-title":"J Immunol Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30347","article-title":"Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma","volume":"70","author":"Sun","year":"2019","journal-title":"Hepatol Baltim Md"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021747","article-title":"Stress Signals Activate Natural Killer Cells","volume":"196","author":"Long","year":"2002","journal-title":"J Exp Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/cdd.2013.26","article-title":"Molecular Mechanisms of Natural Killer Cell Activation in Response to Cellular Stress","volume":"21","author":"Chan","year":"2014","journal-title":"Cell Death Differ"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004441","article-title":"Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells","volume":"10","author":"Luetke-Eversloh","year":"2014","journal-title":"PloS Pathog"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.04.005","article-title":"Critical Role of CD2 Co-Stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans","volume":"15","author":"Liu","year":"2016","journal-title":"Cell Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coi.2015.11.003","article-title":"SLAM Family Receptors in Normal Immunity and Immune Pathologies","volume":"38","author":"Wu","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/cancers11010055","article-title":"Exploiting NK Cell Surveillance Pathways for Cancer Therapy","volume":"11","author":"Barrow","year":"2019","journal-title":"Cancers"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nri2604","article-title":"Oncogenic Stress Sensed by the Immune System: Role of NK Cell Receptors","volume":"9","author":"Raulet","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00573","article-title":"Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory","volume":"6","author":"Della Chiesa","year":"2015","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153236","article-title":"Activation by SLAM Family Receptors Contributes to NK Cell Mediated \u201cMissing-Self\u201d Recognition","volume":"11","author":"Alari-Pahissa","year":"2016","journal-title":"PloS One"},{"key":"B90","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1600-065X.2006.00453.x","article-title":"NK Cell Regulation by SLAM Family Receptors and SAP-Related Adapters","volume":"214","author":"Veillette","year":"2006","journal-title":"Immunol Rev"},{"key":"B91","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/JLB.MA0618-231R","article-title":"CRTAM+ NK Cells Endowed With Suppressor Properties Arise in Leukemic Bone Marrow","volume":"105","author":"Ram\u00edrez-Ram\u00edrez","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3676","article-title":"Inducible Costimulator Costimulates Cytotoxic Activity and IFN-\u03b3 Production in Activated Murine NK Cells","volume":"169","author":"Ogasawara","year":"2002","journal-title":"J Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e1002045","DOI":"10.1371\/journal.ppat.1002045","article-title":"Dual Function of the NK Cell Receptor 2b4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells","volume":"7","author":"Schlaphoff","year":"2011","journal-title":"PloS Pathog"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3667","article-title":"Costimulation of Multiple NK Cell Activation Receptors by NKG2D","volume":"169","author":"Ho","year":"2002","journal-title":"J Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030768","article-title":"NK Cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias","volume":"9","author":"Zambello","year":"2020","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/intimm\/13.4.397","article-title":"Signaling Through CD38 Induces NK Cell Activation","volume":"13","author":"Mallone","year":"2001","journal-title":"Int Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.1741","article-title":"CD27-Mediated Activation of Murine NK Cells","volume":"164","author":"Takeda","year":"2000","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031328","article-title":"The Bone Marrow Microenvironment in Health and Myeloid Malignancy","volume":"8","author":"Gal\u00e1n-D\u00edez","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/157496","article-title":"Bone Marrow Microenvironment in Multiple Myeloma Progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J BioMed Biotechnol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cr.2018.08.002","article-title":"Hematopoiesis and Microenvironment in Hematological Malignancies","volume":"7","author":"Cheng","year":"2018","journal-title":"Cell Regen"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The Bone-Marrow Niche in MDS and MGUS: Implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66517","article-title":"BM Mesenchymal Stromal Cell\u2013Derived Exosomes Facilitate Multiple Myeloma Progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2621","article-title":"The Metastatic Niche: Adapting the Foreign Soil","volume":"9","author":"Psaila","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1835836","article-title":"Cytokine and Chemokine Profile in Patients With Multiple Myeloma Treated With Bortezomib","volume":"2020","author":"Robak","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.06.012","article-title":"The Cytokine\/Chemokine Pattern in the Bone Marrow Environment of Multiple Myeloma Patients","volume":"38","author":"Cao","year":"2010","journal-title":"Exp Hematol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00348","article-title":"Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities","volume":"4","author":"Botta","year":"2014","journal-title":"Front Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-019-00232-2","article-title":"Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response","volume":"12","author":"Lorenzo-Sanz","year":"2019","journal-title":"Cancer Microenviron"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058504","article-title":"The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma","volume":"8","author":"Zheng","year":"2013","journal-title":"PloS One"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone Marrow Mesenchymal Stem Cells are Abnormal in Multiple Myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.65","article-title":"Mesenchymal Stem Cells From Multiple Myeloma Patients Display Distinct Genomic Profile as Compared With Those From Normal Donors","volume":"23","author":"Garayoa","year":"2009","journal-title":"Leukemia"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00931-3","article-title":"The Multiple Myeloma Microenvironment is Defined by an Inflammatory Stromal Cell Landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584683","article-title":"Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes","volume":"10","author":"Fairfield","year":"2021","journal-title":"Front Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jbo.2018.09.001","article-title":"Osteoblast Suppression in Multiple Myeloma Bone Disease","volume":"13","author":"Adamik","year":"2018","journal-title":"J Bone Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.07.012","article-title":"Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone","volume":"186","author":"Trotter","year":"2016","journal-title":"Am J Pathol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple Myeloma Bone Disease: Pathophysiology of Osteoblast Inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1038\/s41467-019-12296-1","article-title":"Transcriptomic Profiling of the Myeloma Bone-Lining Niche Reveals BMP Signalling Inhibition to Improve Bone Disease","volume":"10","author":"Gooding","year":"2019","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in Biology of Multiple Myeloma: Clinical Applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1322.047","article-title":"Targeting Multiple Myeloma Cells and Their Bone Marrow Microenvironment","volume":"1028","author":"Pagnucco","year":"2004","journal-title":"Ann NY Acad Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone Marrow Angiogenesis and Progression in Multiple Myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1338","article-title":"Endothelial Cells in the Bone Marrow of Patients With Multiple Myeloma","volume":"102","author":"Vacca","year":"2003","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.412","article-title":"Four Proteins Governing Overangiogenic Endothelial Cell Phenotype in Patients With Multiple Myeloma are Plausible Therapeutic Targets","volume":"31","author":"Berardi","year":"2012","journal-title":"Oncogene"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.193","article-title":"Low Bone Marrow Oxygen Tension and Hypoxia-Inducible Factor-1\u03b1 Overexpression Characterize Patients With Multiple Myeloma: Role on the Transcriptional and Proangiogenic Profiles of CD138+ Cells","volume":"24","author":"Colla","year":"2010","journal-title":"Leukemia"},{"key":"B125","doi-asserted-by":"publisher","first-page":"166655","DOI":"10.1016\/j.jmb.2020.09.014","article-title":"Plasma Cells: From Cytokine Production to Regulation in Experimental Autoimmune Encephalomyelitis","volume":"433","author":"Wang","year":"2021","journal-title":"J Mol Biol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02768","article-title":"Plasma Cells, the Next Generation: Beyond Antibody Secretion","volume":"10","author":"Pioli","year":"2019","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coi.2014.02.009","article-title":"From the Regulatory Functions of B Cells to the Identification of Cytokine-Producing Plasma Cell Subsets","volume":"28","author":"Dang","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205868","article-title":"Comparison of Gene Expression Profiling Between Malignant and Normal Plasma Cells With Oligonucleotide Arrays","volume":"21","author":"De Vos","year":"2002","journal-title":"Oncogene"},{"key":"B129","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage Diversity Enhances Tumor Progression and Metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30102","article-title":"High Numbers of CD163+ Tumor-Associated Macrophages Correlate With Poor Prognosis in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/183602","article-title":"Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment","volume":"2013","author":"Berardi","year":"2013","journal-title":"J Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid Derived Suppressor Cells Are Numerically, Functionally and Phenotypically Different in Patients With Multiple Myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12036","article-title":"The Immunosuppressive Tumour Network: Myeloid-Derived Suppressor Cells, Regulatory T Cells and Natural Killer T Cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-Induced CD14+HLA-DR (-\/Low) Myeloid-Derived Suppressor Cells Correlate With Tumor Progression and Outcome of Therapy in Multiple Myeloma Patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol Immunother CII"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) are Increased in Multiple Myeloma and Are Driven by Dysfunctional Mesenchymal Stem Cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804253","article-title":"Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells","volume":"183","author":"Hanson","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45862","article-title":"Tumor-Infiltrating Myeloid Cells Induce Tumor Cell Resistance to Cytotoxic T Cells in Mice","volume":"121","author":"Lu","year":"2011","journal-title":"J Clin Invest"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143776","article-title":"Mononuclear Myeloid-Derived \u201cSuppressor\u201d Cells Express RAE-1 and Activate Natural Killer Cells","volume":"112","author":"Nausch","year":"2008","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9270","article-title":"Granulocytic Myeloid-Derived Suppressor Cells Promote Angiogenesis in the Context of Multiple Myeloma","volume":"7","author":"Binsfeld","year":"2016","journal-title":"Oncotarget"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells Through Membrane-Bound TGF-Beta 1","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0691","article-title":"Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function","volume":"24","author":"Stiff","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12935-018-0687-8","article-title":"Increased Activated Regulatory T Cell Subsets and Aging Treg-Like Cells in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: A Case Control Study","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T Regulatory Cells Are Associated With Adverse Clinical Features and Predict Progression in Multiple Myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PloS One"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T Regulatory Cells in Multiple Myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1579324","article-title":"Evaluating the Role of Tregs in the Progression of Multiple Myeloma","volume":"60","author":"Lad","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/293479","article-title":"The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma","volume":"2012","author":"Braga","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 Produced by Th17 Cells Promotes Myeloma Cell Growth and Inhibits Immune Function in Multiple Myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-Term Survival in Multiple Myeloma is Associated With a Distinct Immunological Profile, Which Includes Proliferative Cytotoxic T-Cell Clones and a Favourable Treg\/Th17 Balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"B149","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.smim.2019.06.002","article-title":"ILCs in Hematologic Malignancies: Tumor Cell Killers and Tissue Healers","volume":"41","author":"Blom","year":"2019","journal-title":"Semin Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA Class I, NKG2D, and Natural Cytotoxicity Receptors Regulate Multiple Myeloma Cell Recognition by Natural Killer Cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(87)90158-5","article-title":"Inhibition of Clonogenic Growth of Fresh Leukemia Cells by Unstimulated and IL-2 Stimulated NK Cells of Normal Donors","volume":"11","author":"Lotzov\u00e1","year":"1987","journal-title":"Leuk Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-Myeloma Activity of Natural Killer Lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br J Haematol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00293","article-title":"Role of Distinct Natural Killer Cell Subsets in Anticancer Response","volume":"8","author":"Stabile","year":"2017","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.87","article-title":"Natural Killer Cell Immune Escape in Acute Myeloid Leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical Stage-Depending Decrease of NK Cell Activity in Multiple Myeloma Patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01444","article-title":"Restoring Natural Killer Cell Immunity Against Multiple Myeloma in the Era of New Drugs","volume":"8","author":"Pittari","year":"2017","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.4651006.x","article-title":"Analysis of Natural Killer-Associated Antigens in Peripheral Blood and Bone Marrow of Multiple Myeloma Patients and Prognostic Implications","volume":"93","author":"Garc\u00eda-Sanz","year":"1996","journal-title":"Br J Haematol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/421702","article-title":"Hematological Malignancies Escape From NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications","volume":"2012","author":"Farnault","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100930","article-title":"NK Cell Infiltration is Associated With Improved Overall Survival in Solid Cancers: A Systematic Review and Meta-Analysis","volume":"14","author":"Nersesian","year":"2021","journal-title":"Transl Oncol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pharmthera.2016.09.006","article-title":"The Functional Interplay Between Systemic Cancer and the Hematopoietic Stem Cell Niche","volume":"168","author":"Giles","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B163","first-page":"99","article-title":"Natural Killer Cell Frequency and Function in Patients With Monoclonal Gammopathies","volume":"37","author":"Famularo","year":"1992","journal-title":"J Clin Lab Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00443.x","article-title":"Natural Killer Cell Activity in Monoclonal Gammopathies: Relation to Disease Activity","volume":"45","author":"Osterborg","year":"1990","journal-title":"Eur J Haematol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009871","article-title":"Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-Risk B- and T-Cell Acute Lymphoblastic Leukemia","volume":"138","author":"Duault","year":"2021","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e1238","DOI":"10.1002\/cti2.1238","article-title":"Arrested Development: Suppression of NK Cell Function in the Tumor Microenvironment","volume":"10","author":"Riggan","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01945","article-title":"Molecular Regulation of NK Cell Maturation","volume":"11","author":"Bi","year":"2020","journal-title":"Front Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301891110","article-title":"Acute Myeloid Leukemia Does Not Deplete Normal Hematopoietic Stem Cells But Induces Cytopenias by Impeding Their Differentiation","volume":"110","author":"Miraki-Moud","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4535","article-title":"Tumor Growth Impedes Natural-Killer-Cell Maturation in the Bone Marrow","volume":"108","author":"Richards","year":"2006","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.610789","article-title":"Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front Immunol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.81","article-title":"Leukemia Cell Infiltration Causes Defective Erythropoiesis Partially Through MIP-1\u03b1\/Ccl3","volume":"30","author":"Wang","year":"2016","journal-title":"Leukemia"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.020","article-title":"Natural Killer Cell Deficiency","volume":"132","author":"Orange","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.2.885","article-title":"Prostaglandin E2 Suppressed IL-15-Mediated Human NK Cell Function Through Down-Regulation of Common Gamma-Chain","volume":"166","author":"Joshi","year":"2001","journal-title":"J Immunol Baltim Md 1950"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711621","article-title":"Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation","volume":"12","author":"Mishra","year":"2021","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous Treatment With IL-15 Exhausts Human NK Cells via a Metabolic Defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"key":"B178","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/ijms22073587","article-title":"Immunological Prognostic Factors in Multiple Myeloma","volume":"22","author":"B\u0119bnowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B179","article-title":"A Disturbance of the IL-2\/IL-2 Receptor System Parallels the Activity of Multiple Myeloma","volume":"84","author":"Vacca","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111229","article-title":"Loss-Of-Function Mutations in the IL-21 Receptor Gene Cause a Primary Immunodeficiency Syndrome","volume":"210","author":"Kotlarz","year":"2013","journal-title":"J Exp Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2048","article-title":"IL-21 Induces the Functional Maturation of Murine NK Cells","volume":"172","author":"Brady","year":"2004","journal-title":"J Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.08.039","article-title":"IL-21: A Novel IL-2\u2013Family Lymphokine That Modulates B, T, and Natural Killer Cell Responses","volume":"112","author":"Habib","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12291","article-title":"The Natural Killer Cell Dysfunction of Aged Mice is Due to the Bone Marrow Stroma and Is Not Restored by IL-15\/IL-15r\u03b1 Treatment","volume":"14","author":"Nair","year":"2015","journal-title":"Aging Cell"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/srep22097","article-title":"Regulatory T Cells Inhibit CD34+ Cell Differentiation Into NK Cells by Blocking Their Proliferation","volume":"6","author":"Pedroza-Pacheco","year":"2016","journal-title":"Sci Rep"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2388","article-title":"TGF-\u03b2 is Responsible for NK Cell Immaturity During Ontogeny and Increased Susceptibility to Infection During Mouse Infancy","volume":"13","author":"Marcoe","year":"2012","journal-title":"Nat Immunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40121-017-0146-1","article-title":"Infections in Cancer Patients With Solid Tumors: A Review","volume":"6","author":"Rolston","year":"2017","journal-title":"Infect Dis Ther"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1086\/605664","article-title":"Infections in Patients With Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01242","article-title":"Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00402","article-title":"Dysregulation of Chemokine\/Chemokine Receptor Axes and NK Cell Tissue Localization During Diseases","volume":"7","author":"Bernardini","year":"2016","journal-title":"Front Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/ni1523","article-title":"Natural Killer Cell Trafficking In Vivo Requires a Dedicated Sphingosine 1-Phosphate Receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nat Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-106203","article-title":"CCL3 and CXCL12 Regulate Trafficking of Mouse Bone Marrow NK Cell Subsets","volume":"111","author":"Bernardini","year":"2008","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362574","article-title":"Sequential Desensitization of CXCR4 and S1P5 Controls Natural Killer Cell Trafficking","volume":"118","author":"Mayol","year":"2011","journal-title":"Blood"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1320","article-title":"Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment","volume":"75","author":"Ponzetta","year":"2015","journal-title":"Cancer Res"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00496","article-title":"Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients","volume":"10","author":"Lim","year":"2019","journal-title":"Front Immunol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cytogfr.2020.12.003","article-title":"Chemokine Networks Modulating Natural Killer Cell Trafficking to Solid Tumors","volume":"59","author":"Yao","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2003.10.036","article-title":"CXCR3-Binding Chemokines in Multiple Myeloma","volume":"207","author":"Pellegrino","year":"2004","journal-title":"Cancer Lett"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1151511","article-title":"Monokine Induced by Interferon Gamma (MIG\/CXCL9) Is an Independent Prognostic Factor in Newly Diagnosed Myeloma","volume":"57","author":"Bolomsky","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B198","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s40425-019-0751-5","article-title":"Targeting of CXCR3 Improves Anti-Myeloma Efficacy of Adoptively Transferred Activated Natural Killer Cells","volume":"7","author":"Bonanni","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130032","article-title":"Downregulation of CXCR4 in Metastasized Breast Cancer Cells and Implication in Their Dormancy","volume":"10","author":"Nobutani","year":"2015","journal-title":"PloS One"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00012","article-title":"Differential Chemotactic Receptor Requirements for NK Cell Subset Trafficking Into Bone Marrow","volume":"4","author":"Bernardini","year":"2013","journal-title":"Front Immunol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277897","article-title":"CXCL12-CXCR4 Chemokine Signaling Is Essential for NK-Cell Development in Adult Mice","volume":"117","author":"Noda","year":"2011","journal-title":"Blood"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key Chemokines Direct Migration of Immune Cells in Solid Tumors","author":"Kohli","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0148","article-title":"Lessons Learned From Checkpoint Blockade Targeting PD-1 in Multiple Myeloma","volume":"7","author":"Lesokhin","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 Ligands: From Discovery to Clinical Application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 Axis in Multiple Myeloma: A Dream or a Reality","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"B206","doi-asserted-by":"publisher","first-page":"E3285","DOI":"10.3390\/cancers12113285","article-title":"The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy","volume":"12","author":"Quatrini","year":"2020","journal-title":"Cancers"},{"key":"B207","doi-asserted-by":"publisher","first-page":"12641","DOI":"10.1038\/s41598-020-69616-5","article-title":"PD-L1 Expression in Bone Marrow Plasma Cells as a Biomarker to Predict Multiple Myeloma Prognosis: Developing a Nomogram-Based Prognostic Model","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040924","article-title":"PD-L1\u2013PD-1 Pathway in the Pathophysiology of Multiple Myeloma","volume":"12","author":"Tamura","year":"2020","journal-title":"Cancers"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 Axis Modulates the Natural Killer Cell Versus Multiple Myeloma Effect: A Therapeutic Target for CT-011, a Novel Monoclonal Anti\u2013PD-1 Antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L Inhibitory Pathway Affects Both CD4(+) and CD8(+) T Cells and Is Overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur J Immunol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127261","article-title":"PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells But Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets","volume":"134","author":"Davis","year":"2019","journal-title":"Blood"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.209","article-title":"Increased Expression of Programmed Cell Death Protein 1 on NK Cells Inhibits NK-Cell-Mediated Anti-Tumor Function and Indicates Poor Prognosis in Digestive Cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.05.022","article-title":"The Depths of PD-1 Function Within the Tumor Microenvironment Beyond CD8+ T Cells","author":"Laba","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/srep39296","article-title":"PD-L1+MDSCs are Increased in HCC Patients and Induced by Soluble Factor in the Tumor Microenvironment","volume":"6","author":"Iwata","year":"2016","journal-title":"Sci Rep"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1247135","article-title":"The Expression Profiles and Regulation of PD-L1 in Tumor-Induced Myeloid-Derived Suppressor Cells","volume":"5","author":"Lu","year":"2016","journal-title":"OncoImmunol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.213","article-title":"Marrow Stromal Cells Induce B7-H1 Expression on Myeloma Cells, Generating Aggressive Characteristics in Multiple Myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2018-99-119099","article-title":"The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"B218","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12865-021-00434-8","article-title":"Downregulation of NKG2DLs by TGF-\u03b2 in Human Lung Cancer Cells","volume":"22","author":"Lee","year":"2021","journal-title":"BMC Immunol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The Common Gamma-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and its Ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J Immunol Baltim Md 1950"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16281","article-title":"Tumor-Derived IL-18 Induces PD-1 Expression on Immunosuppressive NK Cells in Triple-Negative Breast Cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-\u03b1 Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J Immunol Baltim Md 1950"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 Is a Novel Direct Target of HIF-1\u03b1, and its Blockade Under Hypoxia Enhanced MDSC-Mediated T Cell Activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B223","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.202.Supp.194.37","article-title":"Hypoxia-Inducible Factor-1\u03b1 is Upregulated in Natural Killer Cells by Interleukin-2 and Hypoxia via PI3K\/mTOR Signaling Pathway","volume":"202","author":"Cluff","year":"2019","journal-title":"J Immunol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1264562","article-title":"High NKG2A Expression Contributes to NK Cell Exhaustion and Predicts a Poor Prognosis of Patients With Liver Cancer","volume":"6","author":"Sun","year":"2016","journal-title":"OncoImmunol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100354108","article-title":"HLA-E Expression by Gynecological Cancers Restrains Tumor-Infiltrating CD8+ T Lymphocytes","volume":"108","author":"Gooden","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B226","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1479-5876-9-184","article-title":"High Expression of HLA-E in Colorectal Carcinoma Is Associated With a Favorable Prognosis","volume":"9","author":"Benevolo","year":"2011","journal-title":"J Transl Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01415","article-title":"NKG2A Expression Is Not Per Se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment","volume":"9","author":"Mahaweni","year":"2018","journal-title":"Front Immunol"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123955","article-title":"Blocking Expression of Inhibitory Receptor NKG2A Overcomes Tumor Resistance to NK Cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J Clin Invest"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.135301","article-title":"Effects of Anti-NKG2A Antibody Administration on Leukemia and Normal Hematopoietic Cells","volume":"101","author":"Ruggeri","year":"2016","journal-title":"Haematologica"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670673","article-title":"HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15564","article-title":"IFN-Gamma Protects Short-Term Ovarian Carcinoma Cell Lines From CTL Lysis via a CD94\/NKG2A-Dependent Mechanism","volume":"110","author":"Malmberg","year":"2002","journal-title":"J Clin Invest"},{"key":"B232","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1479-5876-11-247","article-title":"HLA-Dependent Tumour Development: A Role for Tumour Associate Macrophages","volume":"11","author":"Marchesi","year":"2013","journal-title":"J Transl Med"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y","article-title":"Transforming Growth Factor-Beta-Induced Expression of CD94\/NKG2A Inhibitory Receptors in Human T Lymphocytes","volume":"29","author":"Bertone","year":"1999","journal-title":"Eur J Immunol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/405295","article-title":"Influence of In Vitro IL-2 or IL-15 Alone or in Combination With Hsp-70-Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors","volume":"2013","author":"Hromadnikova","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/s0171-2985(00)80037-6","article-title":"NK Cells Modulate MHC Class I Expression on Tumor Cells and Their Susceptibility to Lysis","volume":"202","author":"Jonges","year":"2000","journal-title":"Immunobiology"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"key":"B237","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/abbs\/gmu041","article-title":"Myeloma Cells Resistance to NK Cell Lysis Mainly Involves an HLA Class I-Dependent Mechanism","volume":"46","author":"Gao","year":"2014","journal-title":"Acta Biochim Biophys Sin"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1093721","article-title":"Overexpression of KIR Inhibitory Ligands (HLA-I) Determines That Immunosurveillance of Myeloma Depends on Diverse and Strong NK Cell Licensing","volume":"5","author":"Mart\u00ednez-S\u00e1nchez","year":"2015","journal-title":"OncoImmunol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1694-4","article-title":"Optimal Selection of Natural Killer Cells to Kill Myeloma: The Role of HLA-E and NKG2A","volume":"64","author":"Sarkar","year":"2015","journal-title":"Cancer Immunol Immunother CII"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02848","article-title":"Tuning Natural Killer Cell Anti-Multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A","volume":"9","author":"Mahaweni","year":"2018","journal-title":"Front Immunol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1582","article-title":"Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise","volume":"22","author":"Felices","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201747128","article-title":"KIR Downregulation by IL-12\/15\/18 Unleashes Human NK Cells From KIR\/HLA-I Inhibition and Enhances Killing of Tumor Cells","volume":"48","author":"Ewen","year":"2018","journal-title":"Eur J Immunol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2017.00084","article-title":"Transforming Growth Factor-\u03b22 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers","volume":"4","author":"Berglund","year":"2017","journal-title":"Front Vet Sci"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an Emerging Immune Checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3673","article-title":"Nectin-2 Expression on Malignant Plasma Cells Is Associated With Better Response to TIGIT Blockade in Multiple Myeloma","volume":"26","author":"Lozano","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B247","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00335-018-9770-7","article-title":"Interaction of PVR\/PVRL2 With TIGIT\/DNAM-1 as a Novel Immune Checkpoint Axis and Therapeutic Target in Cancer","volume":"29","author":"Stamm","year":"2018","journal-title":"Mamm Genome Off J Int Mamm Genome Soc"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT Immune Checkpoint Blockade Restores CD8+ T-Cell Immunity Against Multiple Myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"B249","doi-asserted-by":"publisher","first-page":"E440","DOI":"10.3390\/cancers12020440","article-title":"Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells","volume":"12","author":"Mekhloufi","year":"2020","journal-title":"via NF-kB Transcription Factor Cancers"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0839","article-title":"Adaptive NK Cells With Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells","volume":"76","author":"Sarhan","year":"2016","journal-title":"Cancer Res"},{"key":"B251","doi-asserted-by":"publisher","first-page":"E2417","DOI":"10.3390\/cancers12092417","article-title":"TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy With Activation","volume":"12","author":"Dao","year":"2020","journal-title":"Cancers"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584530","article-title":"Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-\u03bab Signal Pathways","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 Expression Is Associated With Tumor Antigen-Specific CD8+ T Cell Dysfunction in Melanoma Patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"B254","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1182\/blood-2019-127769","article-title":"The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia","volume":"134","author":"Fu","year":"2019","journal-title":"Blood"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01085-12","article-title":"Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice","volume":"87","author":"Golden-Mason","year":"2013","journal-title":"J Virol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1159\/000487730","article-title":"Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma","volume":"45","author":"Xu","year":"2018","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"B257","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3892\/etm.2021.10137","article-title":"HMGB1 Enhances Chemotherapy Resistance in Multiple Myeloma Cells by Activating the Nuclear Factor-\u03bab Pathway","volume":"22","author":"Ning","year":"2021","journal-title":"Exp Ther Med"},{"key":"B258","article-title":"Downregulation of CEACAM6 Gene Expression in Laryngeal Squamous Cell Carcinoma Is an Effect of DNA Hypermethylation and Correlates With Disease Progression","volume":"8","author":"Bednarek","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired Activating Receptor Expression Pattern in Natural Killer Cells From Patients With Multiple Myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1050-2","article-title":"Human NK Cells in Acute Myeloid Leukaemia Patients: Analysis of NK Cell-Activating Receptors and Their Ligands","volume":"60","author":"Sanchez-Correa","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12082","article-title":"Differential Expression of Natural Killer Cell Activating Receptors in Blood Versus Bone Marrow in Patients With Monoclonal Gammopathy","volume":"139","author":"Costello","year":"2013","journal-title":"Immunol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D Immunoreceptor and its Ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B263","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cellimm.2006.03.002","article-title":"Soluble ULBP Suppresses Natural Killer Cell Activity via Down-Regulating NKG2D Expression","volume":"239","author":"Song","year":"2006","journal-title":"Cell Immunol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108925","article-title":"Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion","volume":"9","author":"Lundholm","year":"2014","journal-title":"PloS One"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1038\/nature01112","article-title":"Tumour-Derived Soluble MIC Ligands Impair Expression of NKG2D and T-Cell Activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nat"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258867","article-title":"A Shed NKG2D Ligand That Promotes Natural Killer Cell Activation and Tumor Rejection","volume":"348","author":"Deng","year":"2015","journal-title":"Sci"},{"key":"B267","article-title":"Macrophage Migration Inhibitory Factor (MIF) Contributes to the Immune Escape of Ovarian Cancer by Downregulating NKG2D","volume":"180","author":"Krockenberger","year":"2008","journal-title":"J Immunol Baltim Md 1950"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.09.011","article-title":"IDO1 Impairs NK Cell Cytotoxicity by Decreasing NKG2D\/NKG2DLs","volume":"103","author":"Zhang","year":"2018","journal-title":"via promoting miR-18a Mol Immunol"},{"key":"B269","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-Transduced Natural Killer Cells Efficiently Target Multiple Myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM Family Receptor Involved in Immune Regulation, Is a Therapeutic Target in Multiple Myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 Promotes the Growth of Myeloma Cells via Homophilic Interaction With Surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26196","article-title":"Clinical Impact of Serum Soluble SLAMF7 in Multiple Myeloma","volume":"9","author":"Ishibashi","year":"2018","journal-title":"Oncotarget"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2870","article-title":"FDA Drug Approval: Elotuzumab in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","volume":"23","author":"Gormley","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B276","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the Treatment of Multiple Myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front Immunol"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002594","article-title":"TGF-\u03b21 Down-Regulation of NKG2D\/DAP10 and 2B4\/SAP Expression on Human NK Cells Contributes to HBV Persistence","volume":"8","author":"Sun","year":"2012","journal-title":"PloS Pathog"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0730640100","article-title":"Transforming Growth Factor Beta 1 Inhibits Expression of NKp30 and NKG2D Receptors: Consequences for the NK-Mediated Killing of Dendritic Cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.07.032","article-title":"2b4 (CD244) is a non-MHC Binding Receptor With Multiple Functions on Natural Killer Cells and CD8+ T Cells","volume":"42","author":"McNerney","year":"2005","journal-title":"Mol Immunol"},{"key":"B281","first-page":"60","article-title":"A Novel Function-Associated Molecule Related to non-MHC-Restricted Cytotoxicity Mediated by Activated Natural Killer Cells and T Cells","volume":"151","author":"Garni-Wagner","year":"1993","journal-title":"J Immunol Baltim Md 1950"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02809","article-title":"The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment","volume":"9","author":"Agresta","year":"2018","journal-title":"Front Immunol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0311177","article-title":"Characterization of the Nature of Granulocytic Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice","volume":"91","author":"Youn","year":"2012","journal-title":"J Leukoc Biol"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121788","article-title":"Identification of an ADAM17 Cleavage Region in Human CD16 (Fc\u03b3riii) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells","volume":"10","author":"Jing","year":"2015","journal-title":"PloS One"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1007\/BF00920634","article-title":"Correlation Between Soluble Serum CD16 (Scd16) Levels and Disease Stage in Patients With Multiple Myeloma","volume":"13","author":"Mathiot","year":"1993","journal-title":"J Clin Immunol"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00909","article-title":"The Natural Cytotoxicity Receptors in Health and Disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front Immunol"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00369","article-title":"Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions With Diverse Ligands and Alterations in Splice Variant Expression","volume":"8","author":"Pazina","year":"2017","journal-title":"Front Immunol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.01.010","article-title":"NKp46 Receptor-Mediated Interferon-\u03b3 Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis","volume":"48","author":"Glasner","year":"2018","journal-title":"Immun"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102461","article-title":"Recognition and Prevention of Tumor Metastasis by the NK Receptor Nkp46\/NCR1","volume":"188","author":"Glasner","year":"2012","journal-title":"J Immunol Baltim Md 1950"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6248590","article-title":"Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated With Tumor Progression in Human Gastric Cancer","volume":"2018","author":"Han","year":"2018","journal-title":"J Immunol Res"},{"key":"B291","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2407-9-186","article-title":"Low NKp30, NKp46 and NKG2D Expression and Reduced Cytotoxic Activity on NK Cells in Cervical Cancer and Precursor Lesions","volume":"9","author":"Garcia-Iglesias","year":"2009","journal-title":"BMC Cancer"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.29","article-title":"B7H6-Specific Chimeric Antigen Receptors Lead to Tumor Elimination and Host Antitumor Immunity","volume":"22","author":"Wu","year":"2015","journal-title":"Gene Ther"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00719","article-title":"NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans","volume":"10","author":"Parodi","year":"2019","journal-title":"Front Immunol"},{"key":"B294","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3978\/j.issn.2305-5839.2015.09.08","article-title":"NKp30 and its Ligands: Emerging Players in Tumor Immune Evasion From Natural Killer Cells","volume":"3","author":"Pogge von Strandmann","year":"2015","journal-title":"Ann Transl Med"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3017","article-title":"Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor Nkp30","volume":"74","author":"Schlecker","year":"2014","journal-title":"Cancer Res"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482513","article-title":"Downregulation of the Activating NKp30 Ligand B7-H6 by HDAC Inhibitors Impairs Tumor Cell Recognition by NK Cells","volume":"122","author":"Fiegler","year":"2013","journal-title":"Blood"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.603464","article-title":"Tumor-Released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape From NK Cell Attack","volume":"289","author":"Wang","year":"2014","journal-title":"J Biol Chem"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202693","article-title":"Neuroblastoma-Derived TGF-\u03b21 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells","volume":"190","author":"Castriconi","year":"2013","journal-title":"J Immunol Baltim Md 1950"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343448","article-title":"Hypoxia Downregulates the Expression of Activating Receptors Involved in NK-Cell-Mediated Target Cell Killing Without Affecting ADCC","volume":"43","author":"Balsamo","year":"2013","journal-title":"Eur J Immunol"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15222","article-title":"NKp30 - A Prospective Target for New Cancer Immunotherapy Strategies","volume":"177","author":"Pinheiro","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B301","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab Induces Mechanisms of Immune Activation Through CD38+ NK Cell Targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep Immune Profiling of Patients Treated With Lenalidomide and Dexamethasone With or Without Daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of Daratumumab on Natural Killer Cells and Impact on Clinical Outcomes in Relapsed or Refractory Multiple Myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The Anti-SLAMF7 Antibody Elotuzumab Mediates NK Cell Activation Through Both CD16-Dependent and \u2013Independent Mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"OncoImmunol"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4831","article-title":"Carfilzomib Enhances Natural Killer Cell-Mediated Lysis of Myeloma Linked With Decreasing Expression of HLA Class I","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078535","article-title":"Bortezomib Down-Regulates the Cell-Surface Expression of HLA Class I and Enhances Natural Killer Cell-Mediated Lysis of Myeloma","volume":"111","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.66","article-title":"Modulatory Effects of Bortezomib on Host Immune Cell Functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunother"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"B312","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of Action of Immunomodulatory Drugs (IMiDS) in Multiple Myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.1.210","article-title":"Thalidomide and Immunomodulatory Derivatives Augment Natural Killer Cell Cytotoxicity in Multiple Myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"B314","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular Mechanisms Whereby Immunomodulatory Drugs Activate Natural Killer Cells: Clinical Application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00704","article-title":"One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy","volume":"9","author":"Besson","year":"2018","journal-title":"Front Immunol"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012732","article-title":"Changes in Bone Marrow Innate Lymphoid Cell Subsets in Monoclonal Gammopathy: Target for IMiD Therapy","volume":"1","author":"Kini Bailur","year":"2017","journal-title":"Blood Adv"},{"key":"B317","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.816499\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T14:25:49Z","timestamp":1674397549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.816499\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":317,"alternative-id":["10.3389\/fimmu.2021.816499"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.816499","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"article-number":"816499"}}